For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

Vertex’s new drug Journavx (suzetrigine) has been hailed as a scientific breakthrough because it allays pain without entering the brain, minimizing the risk of addiction and dependence that can ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

For the first time in 25 years, the U.S. Food and Drug Administration has approved a new type of painkiller. Suzetrigine, sold as Journavx, is administered twice daily in 50-milligram oral tablets ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

The United States Food and Drug Administration (FDA) has approved a new non-opioid prescription medication, Journavx ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years. “Today’s approval is an important public health ...